---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-046001"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:12:15.469590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)

## Summary
- Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.
- Operating profit $3.5M, up $1.6M or 84% YoY, driven by higher Elite label product sales.
- Conference call scheduled for Nov 15, 2024 at 11:30 AM EST to discuss results and business update.
- Stockholders can submit financial questions by 7 PM EST on Nov 14 via dianne@elitepharma.com.

## SEC filing metadata
- accession: 0001493152-24-046001
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/0001493152-24-046001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224046001/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-046001
- JSON: https://secwatch.observer/filing/0001493152-24-046001.json
- Plain text: https://secwatch.observer/filing/0001493152-24-046001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.